Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Posted
Calix, Inc is a software-application business based in the US. Calix shares (CALX) are listed on the NYSE and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$5.61 - USD$38.26 |
---|---|
50-day moving average | USD$33.6147 |
200-day moving average | USD$25.5238 |
Wall St. target price | USD$37.4 |
PE ratio | 65.3519 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$0.54 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Calix stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Calix's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Calix's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 65x. In other words, Calix shares trade at around 65x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Calix's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$56.9 million.
The EBITDA is a measure of a Calix's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | USD$541.2 million |
---|---|
Operating margin TTM | 7.97% |
Gross profit TTM | USD$267 million |
Return on assets TTM | 7.25% |
Return on equity TTM | 15.42% |
Profit margin | 6.19% |
Book value | $4.525 |
Market capitalisation | USD$2.2 billion |
TTM: trailing 12 months
There are currently 3.0 million Calix shares held short by investors – that's known as Calix's "short interest". This figure is 7.5% down from 3.3 million last month.
There are a few different ways that this level of interest in shorting Calix shares can be evaluated.
Calix's "short interest ratio" (SIR) is the quantity of Calix shares currently shorted divided by the average quantity of Calix shares traded daily (recently around 875558.84057971). Calix's SIR currently stands at 3.45. In other words for every 100,000 Calix shares traded daily on the market, roughly 3450 shares are currently held short.
However Calix's short interest can also be evaluated against the total number of Calix shares, or, against the total number of tradable Calix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Calix's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Calix shares in existence, roughly 50 shares are currently held short) or 0.0567% of the tradable shares (for every 100,000 tradable Calix shares, roughly 57 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Calix.
Find out more about how you can short Calix stock.
We're not expecting Calix to pay a dividend over the next 12 months.
Over the last 12 months, Calix's shares have ranged in value from as little as $5.61 up to $38.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Calix's is 1.5011. This would suggest that Calix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Calix, Inc., together with its subsidiaries, provides cloud and software platforms, and systems and services required to deliver the unified access network in the United States, the Middle East, Canada, Europe, the Caribbean, and internationally. The company's cloud and software platforms, and systems and services enable communication service providers (CSPs) to provide a range of services, such as basic voice and data, and advanced broadband services. Its premises systems allow CSPs to master the complexity of the smart and connected homes and offer services to differentiate through the delivery of a subscriber experience. The company offers Calix Cloud, an analytics platform that leverages network data and subscriber behavioral data to deliver analytics and intelligence to communications professionals through role specific dashboards; and Calix Marketing Cloud for CSP marketing teams, as well as Calix Support Cloud for CSP customer support teams. It also provides Experience eXtensible Operating System, a carrier class premises operating system and software platform that supports residential, business, and mobile subscribers; and Access eXtensible Operating System, a software platform built for the specific needs of the access network. The company offers its products through its direct sales force and resellers. Calix, Inc. was founded in 1999 and is headquartered in San Jose, California.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.